Halix, a contract development and manufacturing organization (CDMO) of clinical and commercial proteins and viral products, based in the Netherlands, said they have met their major milestone with the interim delivery of their new 6,700 square meter cGMP facility in Leiden Bio Science Park.
 
Following one year of construction, Halix has completed its new state-of-the-art cGMP facility for the development and production of biopharmaceutical drug substances.
 
The new five-level production facility contains a state-of-the-art manufacturing line for viral vaccines and viral vectors and a separate protein manufacturing area with a capacity up to 1,000 liter single-use bioreactors. In addition, lab space is available for process development, analytical development and quality control. All cleanroom areas have a unidirectional process flow and are designed to allow commercial manufacturing of biopharmaceuticals products.
 
“This new facility offers our current and future clients capacity and flexibility for future expansion and will allow for cGMP manufacturing solutions for viral products, proteins, gene therapy and client-specific new technologies,” said Roland Hecht, chief customer officer, Halix.
 
Alex Huybens, chief operations officer, said, “We are very pleased to have met this major milestone for our new manufacturing facility. We have made great progress under very aggressive timelines. After a construction time of just 12 months we are now able to start production of viral products and protein production will follow soon. This milestone aligns with our growth and expansion strategy that will enable us to accommodate the growing market demand as well as our clients’ demands.”